The American College of Emergency Physicians is dedicated to advancing emergency care and to advocating on behalf emergency physicians and the 124 million emergency patients cared for each year. To accomplish this, ACEP is using a new tool to communicate. This TV portal can be embedded on websites and blogs and will automatically be updated as new content comes available!
To view Multimedia News Release, go to http://www.multivu.com/players/English/50856-emergency-medicine-action-fund/
Sermo, Inc. (www.sermo.com), the largest online network in the United States exclusive to physicians, today introduced Sermo Mobile, an application that allows physicians to access the country’s greatest concentration of medical knowledge in real-time. Sermo Mobile builds on Sermo’s current web platform, an online resource where physicians from across 68 specialties and all 50 states collaborate, discuss and consult with each other to provide the highest quality care to their patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51104-sermo-launches-real-time-medicine-mobile-app-for-physicians
Nearly 200 years after the introduction of the stethoscope, the accuracy of a pocket ultrasound device that enables a physician to “look” at a patient’s heart during routine physical exams has been validated for the first time in peer-reviewed research led by Scripps Translational Science Institute (STSI) and Scripps Health.
Roughly the size of a smart phone, the Vscan™ pocket ultrasound used for point of care assessment of heart health could significantly reduce costs from traditional echocardiograms and improve the quality of care. Research was published in the July 5 issue of the Annals of Internal Medicine.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50963-vscan-pocket-ultrasound-echocardiogram-stethoscope
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
This May, Pepto-Bismol is emerging from the medicine cabinet along side of Busy Philipps, star of ABC’s hit comedy Cougar Town, and showing party people how to celebrate Cinco de Mayo all day long. Those eager to start the festivities early can smash a hysterical variety of piñatas on Pepto’s YouTube page in preparation for a night of Mexican food and fun.
To view Multimedia News Release, go to http://www.multivu.com/players/English/49813-pepto-bismol-smashing-cinco-de-mayo-campaign/
It\\\'s that time of year when you may find yourself feeling that dreaded tingle on you lip that you know will eventually turn into a cold sore. Although cold sores can appear on your lip year round due to cold weather, sun exposure, stress, sickness, injury to the mouth or lack of sleep, outbreaks are most prevalent in the winter time. A new, informative and entertaining website, www.MedicineNotMyth.com helps you identify the right treatments that can help you prevent or shorten an outbreak and understand and avoid cold sore triggers.
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
The day when a surgeon can pull a new human vein “off the shelf” for use in life-saving vascular surgeries is now one step closer to reality. New research published in the current issue of the journal Science Translational Medicine demonstrates the efficacy of tissue-engineered vascular grafts (TEVGs) that are immediately available at the time of surgery and have decreased potential for infection, obstruction or clotting. The bioengineering method of producing veins reported in the newly-published research shows promise in both large and small diameter applications, such as for Coronary Artery Bypass Graft (CABG) surgery and for vascular access in hemodialysis.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/humacyte/48336/
In observance of World Arthritis Day, the Arthritis Foundation is calling on Americans to “Do Blue” on Tues., Oct. 12. From dressing head to toe with blue (hair) dos to blue shoes – and everything in between – to lighting up national monuments in blue, the effort aims to raise awareness of arthritis in all its forms and to urge the nation and individuals to take action to reduce the impact of the most common cause of disability in the U.S.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/46624/
Rules-Based Medicine, Inc. (RBM), today announced the widespread commercial availability of VeriPsych™, the first and only blood-based diagnostic test to aid in confirming the diagnosis of recent onset schizophrenia, a potentially devastating and costly mental illness that affects about 24 million people worldwide. VeriPsych is an innovative molecular diagnostic tool designed to complement the healthcare provider’s clinical impression.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/rulesbasedmedicine/46237/
People in the UK, who currently have significantly poorer access to cancer medicines compared to those in Europei, could soon be gaining access to life saving cancer treatments which are currently not available on the NHS, with the launch of the Cancer Drugs Fund. The interim funding of £50 million for cancer drugs made available today is ahead of the introduction of a longer term Cancer Drugs Fund of £600 million from 2011-2014.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/wishingwall/46284/
